Dr Emily Eaton

Emily joined Sygnature in 2012 and has held a number of scientific and commercial roles within the business prior to her appointment as Vice President, Commercial Services in 2023. Owing to her blend of commercial and integrated discovery experience, Emily is uniquely positioned to bridge the commercial and scientific operations functions, ensuring customer-centric commercial engagement to drive successful collaborations and project delivery. She has over 10 years of drug discovery experience and has supported projects from proof of concept to candidate drug selection, across multiple therapeutic areas and target classes.

Emily holds a BSc (Hons.) in Biochemistry and a PhD in Telomere Biology from the University of Nottingham.